Merck-Remepy Alliance Tests Regulatory Limits of PDURS Compliance

Merck's partnership with Remepy signals a broader industry shift toward Prescription Drug Use-Related Software (PDURS) as a formal regulatory category, with direct consequences for how QA and regulatory affairs teams structure submissions, validation protocols, and software lifecycle documentation under FDA oversight.

The alliance is focused on integrating software with drug products in a manner that demonstrates clinical benefit, a threshold that sits at the center of PDURS compliance requirements. As FDA frameworks for software-integrated drug products continue to mature, manufacturers face mounting pressure to align software development controls with GMP expectations, including change control, risk management, and process validation principles consistent with ICH Q10 and 21 CFR Part 211.

Merck is not alone in this space. Other pharmaceutical companies have moved to embrace PDURS-focused strategies, reflecting a wider recognition that software is no longer a peripheral component but a regulated element of the drug-device combination pathway. For regulatory affairs leads, this means software validation and clinical evidence packages must be built in parallel, not sequentially, with the drug development program.

QA directors evaluating similar partnerships should assess how software integration affects sterility assurance boundaries, batch record integrity, and electronic system controls under 21 CFR Part 11. The Merck-Remepy model may serve as an early reference point as FDA guidance on PDURS continues to develop.

Source: Pharmaceutical Industry News, published 29 April 2026 via EIN Presswire.